Literature DB >> 18187925

Shortening of the induction period of allergic asthma in cynomolgus monkeys by Ascaris suum and house dust mite.

Katsumasa Iwashita1, Hirokazu Kawasaki, Masatsugu Sawada, Mika In, Youichi Mataki, Takashi Kuwabara.   

Abstract

The development of non-human primate models of asthma requires a period of time (e.g., 0.5-1 year). To develop the models in a short period, male cynomolgus monkeys were sensitized with dinitrophenyl-Ascaris suum (DNP-As) allergen by intraperitoneal and intramuscular injection and by intratracheal inhalation. All sensitized animals developed positive intradermal skin reaction to DNP-As. Sensitization elevated allergen-specific IgE levels in serum, the number of CCR4-positive T helper lymphocytes in peripheral blood, and IL-4 and IL-5 releases from phorbol 12-myristate 13-acetate- and ionomycin-stimulated peripheral blood. In addition, allergen challenge induced increases in lung resistance, airway inflammation, and hyperresponsiveness to inhaled methacholine. Next, animals were sensitized with house dust mite extracts (HDM) under the similar procedure. In these animals sensitized with DNP-As or HDM, inhaled fluticasone propionate and oral prednisolone inhibited the allergen-induced airway hyperresponsiveness. Taken together, monkey asthma models were successfully developed by sensitization with DNP-As or HDM under a short-term protocol (within 7 weeks). These models should be useful for the evaluation of anti-inflammatory drugs for asthma treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187925     DOI: 10.1254/jphs.fp0071523

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  4 in total

1.  Association between the First Occurrence of Asthma and Residential Greenness in Children and Teenagers in Taiwan.

Authors:  Chia-Jung Hsieh; Pei-Ying Yu; Chun-Ju Tai; Rong-Hwa Jan; Tzai-Hung Wen; Shyang-Woei Lin; Chun-Chieh Tseng
Journal:  Int J Environ Res Public Health       Date:  2019-06-12       Impact factor: 3.390

2.  An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases.

Authors:  Peipei Liu; Zhongzong Pan; Chunyin Gu; Xiaodan Cao; Xiaowu Liu; Jianjian Zhang; Zheng Xiao; Xueping Wang; Haibing Guo; Dianwen Ju; Su-Jun Deng
Journal:  Front Immunol       Date:  2020-11-27       Impact factor: 7.561

3.  Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency.

Authors:  Louise Saul; Debra H Josephs; Keith Cutler; Andrew Bradwell; Panagiotis Karagiannis; Chris Selkirk; Hannah J Gould; Paul Jones; James F Spicer; Sophia N Karagiannis
Journal:  MAbs       Date:  2014-01-14       Impact factor: 5.857

4.  Airway hyper-responsiveness in lipopolysaccharide-challenged common marmosets (Callithrix jacchus).

Authors:  Christoph Curths; Judy Wichmann; Sarah Dunker; Horst Windt; Heinz-Gerd Hoymann; Hans D Lauenstein; Jens Hohlfeld; Tamara Becker; Franz-Josef Kaup; Armin Braun; Sascha Knauf
Journal:  Clin Sci (Lond)       Date:  2014-01       Impact factor: 6.124

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.